Manuel Kaulich

Manuel studied Biotechnology and obtained his PhD from the Max Planck Institute of Biochemistry and the Biozentrum in Basel. For his postdoc, he joined the group of Steven Dowdy at the University of California in San Diego, where he became interested in gene editing technologies. Since December 2015, Manuel is a group leader at the Institute of Biochemistry II at the Medical Faculty of the Goethe University Frankfurt, Germany. His laboratory develops gene editing technologies and applies them to understand cellular transformation and drug resistance. A major achievement of his lab is the development of the 3Cs technology that recently accumulated in the foundation of the university spin-off Vivlion for which Manuel is the Chief Scientific Officer.